Abstract |
Objective To establish a maximum tolerated dose of superselective intraarterial cerebral infusion (SIACI) of Cetuximab after osmotic disruption of the blood-brain barrier (BBB) with mannitol, and examine safety of the procedure in patients with recurrent malignant glioma. Methods A total of 15 patients with recurrent malignant glioma were included in the current study. The starting dose of Cetuximab was 100 mg/m(2) and dose escalation was done to 250 mg/m(2). All patients were observed for 28 days post-infusion for any side effects. Results There was no dose-limiting toxicity from a single dose of SIACI of Cetuximab up to 250 mg/m(2) after osmotic BBB disruption with mannitol. A tolerable rash was seen in 2 patients, anaphylaxis in 1 patient, isolated seizure in 1 patient, and seizure and cerebral edema in 1 patient. Discussion SIACI of mannitol followed by Cetuximab (up to 250 mg/m(2)) for recurrent malignant glioma is safe and well tolerated. A Phase I/II trial is currently underway to determine the efficacy of SIACI of cetuximab in patients with high-grade glioma.
|
Authors | Shamik Chakraborty, Christopher G Filippi, Tamika Wong, Ashley Ray, Sherese Fralin, A John Tsiouris, Bidyut Praminick, Alexis Demopoulos, Heather J McCrea, Imithri Bodhinayake, Rafael Ortiz, David J Langer, John A Boockvar |
Journal | Journal of neuro-oncology
(J Neurooncol)
Vol. 128
Issue 3
Pg. 405-15
(07 2016)
ISSN: 1573-7373 [Electronic] United States |
PMID | 26945581
(Publication Type: Case Reports, Clinical Trial, Phase I, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Immunological
- Diuretics, Osmotic
- Mannitol
- Cetuximab
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Immunological
(administration & dosage, adverse effects)
- Blood-Brain Barrier
(drug effects, metabolism)
- Brain Neoplasms
(diagnostic imaging, drug therapy, metabolism)
- Cetuximab
(administration & dosage, adverse effects)
- Diuretics, Osmotic
(therapeutic use)
- Drug Therapy, Combination
- Female
- Glioma
(diagnostic imaging, drug therapy, metabolism)
- Humans
- Infusions, Intra-Arterial
- Male
- Mannitol
(therapeutic use)
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, metabolism)
- Treatment Outcome
|